Glutathione

Glutathione (GSH) is a tripeptide made from three amino acids — glycine, cysteine, and glutamic acid — and is the most abundant intracellular antioxidant in the human body. It is synthesized in virtually every cell, with the highest concentrations in the liver, where it is central to detoxification of drugs, environmental toxins, and metabolic byproducts. It also supports immune cell function and helps regenerate other antioxidants including vitamins C and E.

GSH levels decline naturally with age, chronic illness, heavy alcohol use, and sustained oxidative stress. Wellness providers administer it by IV infusion, intramuscular injection, or as an oral supplement for claimed benefits including antioxidant support, skin lightening, liver health, and immune enhancement. Of these, the skin-lightening use has the most published human trial data — though the trials are small and the effect sizes modest.

Honest framing: the body’s need for glutathione is well established; the debate is whether supplemental glutathione (especially oral) meaningfully raises tissue levels and produces clinically relevant effects in people who are not deficient. Evidence quality for most wellness uses is grade C — plausible mechanism, limited and inconsistent human RCT data, no approved indication.

Glutathione functions primarily as an electron donor. It reduces reactive oxygen species (ROS) — including hydrogen peroxide and lipid hydroperoxides — by donating a hydrogen atom, becoming glutathione disulfide (GSSG) in the process. Glutathione reductase then regenerates GSH from GSSG using NADPH, creating a continuous antioxidant cycle [1]. GSH also conjugates with reactive electrophiles (phase II detoxification), making them water-soluble for renal or biliary excretion.

For skin pigmentation, glutathione is thought to competitively inhibit tyrosinase — a key enzyme in melanin biosynthesis — and to shift production from darker eumelanin toward lighter pheomelanin. This mechanism underpins its off-label use as a skin-lightening agent. The same antioxidant action is proposed to reduce UV-induced oxidative damage in skin, though both proposed mechanisms are based on in vitro or small human studies rather than large RCTs.

Oral bioavailability was long assumed to be very low, since glutathione can be cleaved by intestinal peptidases before absorption. A 2015 randomized controlled trial by Richie et al. (Eur J Nutr) challenged this assumption: 500 or 1,000 mg/day of oral GSH for six months raised red blood cell and lymphocyte glutathione levels significantly compared to placebo, with the higher dose producing greater increases [2]. This study is encouraging but does not establish that raised blood GSH translates to improved clinical outcomes in healthy adults.

For skin lightening — the most studied clinical application — a 2019 systematic review by Dilokthornsakul et al. (J Cosmet Dermatol) found several small placebo-controlled trials in which oral glutathione (250–1,000 mg/day) produced measurable reductions in melanin index over 4–12 weeks [5]. Effect sizes were modest and trials were short-term with small samples. A 2021 double-blind RCT by Wahab et al. (Int J Dermatol) combining topical and oral glutathione confirmed skin-lightening effects versus placebo, though topical and oral contributions could not be separated [7]. A review by Weschawalit et al. (2017, Clin Cosmet Investig Dermatol) similarly summarized evidence for antimelanogenic and antioxidant skin effects, acknowledging that most trials were small and short [4].

For parenteral use: Sonthalia et al. (2016, Indian J Dermatol Venereol Leprol) provided a balanced critical review of the evidence base, noting widespread clinical use of injectable glutathione for skin lightening despite limited large-scale RCT evidence and documented safety concerns [3]. AlGhamdi et al. (2020, Dermatol Ther) conducted a controlled assessor-blinded study of parenteral glutathione and found a measurable lightening effect on treated skin, but the sample was very small and no long-term follow-up was conducted [6].

Overall, the human evidence for glutathione is grade C. The mechanistic foundation is solid; smaller human trials suggest that oral and parenteral glutathione can raise glutathione levels and modestly affect skin pigmentation. However, no large, well-powered RCT has demonstrated meaningful clinical outcomes (immune function improvement, disease risk reduction, or other hard endpoints) in otherwise healthy adults. Claims of dramatic anti-aging, detox, or immune-boosting effects go well beyond the available evidence.

For oral supplementation, human trials have used 250–1,000 mg/day in single or divided doses, typically with meals. Liposomal oral formulations are marketed as offering improved absorption compared to standard capsules, though published comparative data in humans are limited. For IV infusions, providers commonly use 600–1,200 mg of glutathione per session, often combined with vitamin C, one to three times per week for skin-focused protocols. For intramuscular injection, smaller doses (200–600 mg per session) are typical.

No dose or regimen has been validated in a large controlled clinical trial, so all dosing recommendations reflect clinical convention rather than established evidence. Patients should work with a licensed provider who can assess individual health factors and monitor for adverse effects.

Oral glutathione at study doses appears well tolerated; mild gastrointestinal effects including bloating and loose stools are the most common complaints. IV and IM glutathione carry a risk of infusion or injection reactions including flushing, itching, and, in rare cases, serious hypersensitivity reactions. Rare but severe adverse events including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in association with IV glutathione used for skin lightening — prompting the FDA, Health Canada, and regulatory agencies in the Philippines and Europe to issue warnings against injectable glutathione for this purpose.

Compounded injectable glutathione is not FDA-approved as a drug. Regulatory agencies have specifically warned that injectable glutathione products marketed for skin lightening are not proven safe or effective for that use. People with glucose-6-phosphate dehydrogenase (G6PD) deficiency, severe liver disease, or a history of hypersensitivity to glutathione should avoid injectable forms. Use during pregnancy or breastfeeding is not recommended outside of a medically supervised context.